Antigenos protetores contra infecção de echinococcus granulosus e vacinas contendo tais antigenos

This invention relates to antigenic polypeptides or peptide fragments or variants thereof suitable for use in vaccines to protect hosts susceptible to infection by Echinococcus or Taeniid parasites, particularly infection by E. granulosus. The antigens are preferably obtained by expression of DNA co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DAVID RICHARD MAASS, DAVID DUNCAN HEATH, MARK JOHN RALSTON, STEPHEN BRUCE LAWRENCE, MARSHALL WILLIAM LIGHOWLERS
Format:	Patent
Sprache:	por
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This invention relates to antigenic polypeptides or peptide fragments or variants thereof suitable for use in vaccines to protect hosts susceptible to infection by Echinococcus or Taeniid parasites, particularly infection by E. granulosus. The antigens are preferably obtained by expression of DNA coding therefor in a recombinant host cell. The antigenic polypeptide of the invention includes the amino acid sequence of Figure 4.